Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective of Part B is to compare the PFS of ramucirumab administered in combination with erlotinib versus placebo in combination with erlotinib in previously untreated patients with EGFR mutation-positive metastatic NSCLC.
Inclusion criteria
- EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer